Overt Hepatic Encephalopathy Treatment Market
Global Overt Hepatic Encephalopathy Treatment Market Poised for Significant Growth, Projected High CAGR from 2024-2031
Market Overview:
The global overt hepatic encephalopathy treatment market is anticipated to witness substantial growth, projecting a high Compound Annual Growth Rate (CAGR) during the forecast period from 2024 to 2031. Overt hepatic encephalopathy, a symptomatic impairment of normal brain function resulting from hepatic failure, impacts approximately 40% of cirrhotic patients during therapeutic treatment. The market's evolution is influenced by factors such as government investments, research initiatives, and the development of innovative treatments, including medications like laxatives and antibiotics.
Scope Metrics:
CAGR: High
Size Available for Years: 2021-2030
Forecast Period: 2024-2031
Data Availability: Value (US$)
Segments Covered: Medications, Route of Administration, Distribution Channel, and Region
Regions Covered: North America, Europe, Asia-Pacific, South America, and Middle East & Africa
To know more Insights Download Sample :
Market Dynamics:
Growing funding and acquisitions in developed economies are propelling advancements in healthcare sectors, contributing to the demand for overt hepatic encephalopathy treatment. Notably, on March 28, 2023, Umecrine Cognition secured SEK 31.6 million in fresh finance, advancing medication development for hepatic encephalopathy treatment. The rising utilization of novel technology and increasing research for innovative treatments further fuel market growth.
Segment Analysis:
The antibiotics segment, led by the non-absorbable oral antibiotic rifaximin, holds a significant market share of approximately 39%. Rifaximin, active against a wide range of bacteria, is undergoing dosage and administration updates, including pediatric applications for hyperammonemia treatment in hepatic encephalopathy.
Geographical Share:
North America dominates the market, accounting for around 35% of the share in 2022. The region's growth is attributed to increasing healthcare needs, infrastructure development, and a proactive approach to research and advancements, with the United States leading the way.
COVID-19 Impact Analysis:
The COVID-19 pandemic initially impacted the overt hepatic encephalopathy treatment market due to lockdowns and supply chain disruptions. However, ongoing research and a renewed focus on product efficiency have mitigated the impact, with the market expected to grow steadily.
Key Developments:
On June 19, 2023, XIFAXAN (rifaximin) data by Bausch Health Companies Inc. and Salix Pharmaceuticals was featured in the Cirrhosis and its consequences session at the 2023 European Association for the Study of the Liver (EASL) Congress.
On June 30, 2021, Axcella initiated its Phase 2 clinical trial for AXA1665, a multi-targeted oral candidate for lowering the risk of persistent overt hepatic encephalopathy.
Market Companies:
Major global players in the overt hepatic encephalopathy treatment market include Axcella Therapeutics, COSMO PHARMACEUTICALS, Umecrine Cognition AB, Salix Pharmaceuticals (Bausch Health Companies Inc.), ASKA Pharmaceutical Holdings Co., Ltd., Lupin, Norgine, Teva Pharmaceutical Industries Ltd., Fresenius Kabi Austria GmbH, and Fengchen Group Co., Ltd.
Related Reports:
hereditary hemochromatosis market
eosinophilic esophagitis treatment market
About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian